论文部分内容阅读
目的:分析非小细胞肺癌(non-small cell lung cancer,NSCLC)患者β-tubulin Ⅲ的表达水平与化学治疗(化疗)敏感性的关系。方法:经病理确诊的晚期NSCLC患者以1:2随机分配至对照组和基因型组:对照组使用吉西他滨联合顺铂化疗;基因型组根据ERCC1及RRM1的表达情况进行个体化治疗。检测病理标本中β-tubulin Ⅲ的表达水平,比较β-tubulin Ⅲ蛋白表达水平与临床疗效之间的关系。结果:基因型组最终有118例NSCLC病例可评价,均可成功检测β-tubulin Ⅲ的表达情况。对照组有效率(37.5%)与基因型组有效率(47.5%)比较,差异无统计学意义(P>0.05)。基因型组中各组间有效率比较,差异无统计学意义(P>0.05);但β-tubulinⅢ低表达组有效率(55.1%)显著高于β-tubulin Ⅲ高表达组(36.7%,P<0.05)。结论:在晚期NSCLC腺癌亚型中,β-tubulin Ⅲ低表达患者疗效较好,β-tubulin Ⅲ高表达可能意味着对多西他赛耐药。
OBJECTIVE: To analyze the relationship between the expression of β-tubulin Ⅲ and chemosensitivity in patients with non-small cell lung cancer (NSCLC). Methods: Patients with advanced non-small cell lung cancer (NSCLC) diagnosed by pathology were randomly assigned to control and genotypes at a ratio of 1: 2. Patients in the control group were treated with gemcitabine combined with cisplatin. Genotypes were individually treated with ERCC1 and RRM1. The expression of β-tubulin Ⅲ in pathological specimens was detected and the relationship between β-tubulin Ⅲ protein expression and clinical efficacy was compared. Results: 118 cases of NSCLC were finally evaluated in genotype group, and the expression of β-tubulin Ⅲ could be detected successfully. There was no significant difference between the control group (37.5%) and the genotype group (47.5%) (P> 0.05). There was no significant difference in the effective rates among all groups (P> 0.05). However, the effective rate of low expression group (55.1%) was significantly higher than that of high expression group of β-tubulin Ⅲ (36.7%, P <0.05). CONCLUSIONS: In patients with advanced NSCLC adenocarcinoma, low expression of β-tubulin Ⅲ is more effective and high β-tubulin Ⅲ expression may mean resistance to docetaxel.